Vaccine Development

Biopharma company begins studies of vaccine to produce antistaph antibodies

Published in Vaccine Weekly, June 15th, 2005

Nabi Biopharmaceuticals (NABI) announced that it has initiated bridging and consistency lot studies for its StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine) under development for the prevention of S. aureus bloodstream infections in at-risk adults.

The bridging study is designed to compare the immune response and safety of the StaphVAX material produced by the company's contract manufacturer with that of the StaphVAX lot from the company's phase III clinical trial in end-stage renal disease (ESRD) patients. The consistency lot study is being conducted in healthy adults to compare the safety and immunogenicity of three commercial lots of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-06-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry